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Abstract 
 
Hyperammonemia in neonates and infants affects brain development and causes mental 
retardation. We report that ammonium impaired cholinergic axonal growth and altered 
localization and phosphorylation of intermediate neurofilament protein (NF-M) in rat 
reaggregated brain cell primary cultures. This effect was restricted to the phase of early 
maturation but did not occur after synaptogenesis. Exposure to NH4Cl decreased intracellular 
creatine, phosphocreatine and ADP. We demonstrate that creatine co-treatment protected 
axons from ammonium toxic effects, although this did not restore high energy phosphates. 
The protection by creatine was glial cell dependent. Our findings suggest that means to 
efficiently sustain central nervous system (CNS) creatine concentration in hyperammonemic 
neonates and infants should be assessed to prevent impairment of axonogenesis and 
irreversible brain damage. 
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Introduction 
 
Liver failure and genetic defects affecting the urea cycle lead to hyperammonemia with 
reversible and irreversible neurological damage that might be life-threatening (Podolsky and 
Isselbacher, 1998; Brusilow and Horwich, 2001). Symptoms of irreversible damage include 
cognitive impairment, seizures and cerebral palsy (Flint Beal and Martin, 1998). They mainly 
occur in case of prolonged hyperammonemic crises and/or when blood ammonium reaches 
levels between 180 and 500 µM, during the two first years of life (Msall et al., 1984; Uchino 
et al., 1998; Bachmann et al., 2002a, Bachmann et al., 2002b). In the few reported brain 
autopsies of pediatric patients, Alzheimer type II astrocytes, perivascular spongiosis and 
cystic necrosis at the junction of cortical grey and white matter have been observed (Harding 
et al., 1984; Filloux et al., 1986; Dolman et al., 1988). The mechanisms leading to irreversible 
alterations are not understood. 
 
We have shown previously that mimicking hyperammonemia by adding ammonium in a rat 
reaggregating brain cell culture model causes a reduction in aggregate size, which could be 
due to a deficiency or developmental delay of cellular processes in regions where axons are 
prevalent (Braissant et al., 1999b). There is substantial evidence that creatine (Cr) and the Cr / 
phosphocreatine (PCr) / creatine kinase (CK) system are involved in neuronal growth cone 
activity and axonal elongation (Wang et al., 1998). In addition, the central nervous system 
(CNS) is the main affected target in infants with a creatine-deficiency syndrome due to 
guanidinoacetate methyltransferase, arginine:glycine amidinotransferase or Cr transporter 
deficiencies. Such patients exhibit delayed psychomotor development or bilateral myelination 
delay (Stöckler et al., 1994; Schulze et al., 1997; Salomons et al., 2001; Item et al., 2001). We 
and others have also shown that the synthesis of arginine, the main precursor of creatine, is 
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altered by hyperammonemia (Rao et al., 1995; Braissant et al., 1999b). Taken together, these 
findings suggest that hyperammonemia impairs Cr metabolism and/or transport in the CNS. 
Cr is used by the CNS Cr/PCr/CK system to buffer and supply ATP, particularly to neurons 
(Hemmer and Wallimann, 1993). CNS, at least in the rat, seems dependent on its own Cr 
synthesis (Braissant et al., 2001). 
 
The aim of the present work was to test whether axons were affected by hyperammonemia, 
and whether this could be due to a Cr loss or decrease in brain cells. We used reaggregated 
brain cell cultures prepared from the telencephalon of rat embryos, which provide a three-
dimensional network of neurons and glial cells that progressively acquire a tissue specific 
pattern resembling that of the brain (Honegger et al., 1979; Honegger and Monnet-Tschudi, 
2001). We analyzed the axonal expression of the intermediate neurofilament protein (NF-M, 
160kD) and determined the intracellular levels of Cr, PCr, ATP, ADP and AMP under NH4Cl 
exposure. We identified the neurons impaired in axonal growth by ammonium exposure. 
Finally, we tested the protective effect of Cr on the growth of axons exposed to NH4Cl, and 
the influence of the brain cell developmental stage on the axonal vulnerability to ammonium.
  4 
Materials and Methods 
 
Reaggregated brain cell cultures 
Reaggregated brain cell primary cultures were prepared from mechanically dissociated 
telencephalon of 16-day rat embryos as previously described (Honegger and Monnet-Tschudi, 
2001). Cultures were grown in serum-free, chemically defined medium consisting of 
Dulbecco’s modified Eagle’s medium with high glucose (25 mM) supplemented with insulin 
(0.8 µM), triiodothyronine (30 nM), hydrocortisone-21-phosphate (20 nM), transferrin (1 
µg/ml), biotin (4 µM), vitamin B12 (1 µM), linoleate (10 µM), lipoic acid (1 µM), L-carnitine 
(10 µM), and trace elements (Honegger and Monnet-Tschudi, 2001). Gentamicin sulfate (25 
µg/ml) was used as antibiotic. The cultures were maintained under constant gyratory agitation 
(80 rpm), at 37°C and in an atmosphere of 10 % CO2 / 90 % humidified air. 
 
Two different kinds of aggregate cultures were grown:  
A) Regular mixed-cell aggregates, developing with neurons and glial cells. 
B) Neuron-enriched aggregates, which were obtained by the treatment of the regular 
mixed-cell cultures at days 1 and 2 with cytosine arabinoside (0.4 µM) to eliminate 
the proliferating glioblasts (Honegger and Monnet-Tschudi, 2001). Previous work has 
shown that the neuron-enriched cultures contain > 90% neurons, less than 8% 
astrocytes and very few, if any, oligodendrocytes (Honegger and Pardo, 1999). 
Neuron-enriched cultures received conditioned medium taken from mixed-cell 
(neuron-glia) sister cultures and diluted 1:1 with fresh medium. 
 
Aggregates were grown for 13 or 28 days. Aggregates harvested at 13 days were treated from 
day 5 onwards with NH4Cl and/or Cr, with medium replenishments at days 8 and 11 (5 ml 
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replaced out of 8 ml total). Aggregates harvested at 28 days were treated from day 20 
onwards with NH4Cl and/or Cr, with medium replenishments at days 22, 24 and 26 (5 ml 
replaced out of 8 ml total). On the day of harvest, culture media were recovered, immediately 
centrifuged to remove cell debris, and frozen in liquid nitrogen. Aggregate pellets were 
washed three times with ice cold PBS, and embedded for histology or frozen in liquid 
nitrogen. Until analysis, culture media and aggregate pellets were kept at -80°C. 
 
Histology and immunohistochemistry 
Aggregates were embedded in tissue freezing medium (Jung, Nussloch, Germany), frozen in 
liquid nitrogen cooled isopentane and kept at -80°C until used. For histological staining, 16 
µm thick cryosections were prepared, postfixed 1 hour in 4% paraformaldehyde (PFA) in 
PBS and stained by hematoxylin coloration or Bielschowsky’s silver impregnation (Cox, 
1977). NN-18 (Chemicon International, Temecula CA; Shaw et al., 1986; Harris et al., 1991) 
and RMO-44 (Zymed Laboratories, San Francisco CA; Lee et al., 1987) monoclonal 
antibodies were used for immunohistochemistry against NF-M. Axonal growth cones were 
detected with a monoclonal antibody directed against growth cone associated protein 43 
(GAP43 Chemicon International). Astrocytes and oligodendrocytes were labeled using 
monoclonal antibodies directed against glial fibrillary acidic protein (GFAP, Chemicon 
International) and myelin basic protein (MBP, Boehringer Ingelheim). Cholinergic, GABA-
ergic and glutamatergic neurons were characterized by using monoclonal antibodies against 
choline acetyltransferase (ChAT, Oncogene, Cambridge MA), glutamic acid decarboxylase 
(GAD 65/67 kD, Santa Cruz Biotechnology, Santa Cruz CA) and neuronal excitatory amino 
acid transporter 3 (EAAT3, Santa Cruz Biotechnology) respectively (Furuta et al., 1997; 
Pardo and Honegger, 1999; He et al., 2000). For immunohistochemistry against NF-M, 
GAP43, GFAP, GAD and EAAT3, cryosections (16 µM) were fixed for 1 hour in 4% PFA-
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PBS at room temperature, washed in PBS (3 x 5 min) and permeabilized for 5 min in 0.1% 
sodium citrate and 0.1% Triton X-100. For immunohistochemistry against ChAT, 
cryosections (16 µM) were fixed for 1 min in 5% acetic acid / 95% ethanol at 4°C and washed 
in PBS (3 x 5 min). For immunohistochemistry against MBP, cryosections (16 µM) were 
fixed for 1 hour in 4% PFA-PBS at room temperature, washed in PBS (3x 5 min), dehydrated 
with increasing concentrations of EtOH, delipidated in xylene, rehydrated with decreasing 
concentrations of EtOH, and finally washed in PBS. Sections were then processed for 
immunohistochemistry using the Histostain-Plus kit according to the manufacturer’s protocol 
(Zymed Laboratories). The primary antibody was diluted in 1% bovine serum albumin in PBS 
and applied to sections. After washing, sections were incubated with a biotinylated anti-
mouse IgG secondary antibody followed by a streptavidin-peroxidase conjugate. Peroxidase 
staining was performed for 10 min using aminoethyl carbazole and H2O2 and stopped in 
distilled water. Sections were mounted under glycerol, observed and photographed on an 
Olympus BX50 microscope equipped with a DP-10 digital camera (Olympus Opticals). 
 
Protein dephosphorylation on cryosections 
Cryosections (16 µm thick) were digested 30 min (37°C) with alkaline phosphatase (200 
µg/ml, Roche Biochemicals), in Tris 100mM, NaCl 100mM, MgCl2 50 mM, pH 9.5. Sections 
were washed in PBS, fixed 30 min in 4% PFA-PBS, and washed 3 x 5 min in PBS. 
Immunohistochemistry against NF-M was then performed as described above. 
 
Quantitative western blot analysis 
Mixed-cell and neuron-enriched aggregates were homogenized in 10 mM Tris/HCl pH 7.5 
containing 4 M urea, 0.1 % SDS and protease inhibitors (Complete, Roche, Switzerland). 
Homogenates were centrifuged at 16'000 g for 10 min and supernatants were recovered. 
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Supernatant proteins were measured by the bicinchoninic acid assay (Pierce, USA) and 
diluted at a final concentration of 1 µg/µl in Laemmli sample buffer (Laemmli, 1970). 
Proteins were separated by SDS-PAGE (9% total acrylamide). After transfer of the proteins to 
polyvinylidene difluoride membranes (Immobilon, Millipore, USA), blots were probed with 
NN-18 and RMO-44 anti-NF-M, anti-GAP43 and anti-GFAP monoclonal antibodies. Western 
blots were revealed by chemiluminescence (ECL, Amersham Biosciences, England). The 
radiographs (Kodak X-OMAT AR, USA) were scanned with a ImageScanner (Amersham 
Biosciences, England) and processed by image analysis (ImageMaster 1D, Amersham 
Biosciences, England). 
 
Measure of intracellular Cr, PCr, ATP, ADP and AMP 
Frozen aggregate pellets were suspended in ice-cold 25 mM phosphate buffer pH 7.5 
containing 1 mM iodoacetate and 0.1 mM diadenosine pentaphosphate. Cells were extracted 
with 0.4 M perchloric acid, and neutralized with 2 M K2CO3 followed by a centrifugation at 
16'000 g for 5 min. Supernatants were assayed for adenine nucleotides (ATP, ADP and AMP) 
and creatine compounds (Cr and PCr) according to the isocratic reverse-phase HPLC method 
of Seidl et al. (2000) using an HPLC (Agilent, USA) coupled with a dual absorbance detector. 
The absorbance at 214 nm (for Cr and PCr) and 254 nm (for ATP, ADP and AMP) were 
monitored simultaneously. The acid precipitates of the aggregates were solubilized in 0.1 M 
NaOH, 1 % SDS and their protein content was determined by the bicinchoninic acid assay 
(Pierce, USA). The concentrations of Cr, PCr, ATP, ADP and AMP were expressed as nmol · 
(mg prot)-1. 
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Measure of NH4+, glucose and lactate in culture media 
Ammonium was measured on a Cobas FARA II automate (Roche), using the UV Enzymatic 
Ammonium Kit (Biomérieux, N° 61025). Glucose and lactate were measured on a Hitachi 
917 automate (Roche), using the Glucose Ecoline 100 kit (Merck, N° 1.14891.0001) and the 
Lactate kit (Roche, N° 1 822 837). 
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Results 
 
Net uptake of NH4+ and glucose, and net release of lactate, by mixed-cell aggregate cultures 
exposed to NH4Cl are shown in Table 1. During the whole period of NH4Cl exposure, NH4+ 
uptake by cultures was dose dependent. Glucose uptake and lactate release showed highly 
significant increases at the maximal dose of 5 mM NH4Cl. The extent of metabolic changes 
observed with increasing NH4Cl concentrations paralleled morphological changes in the 
aggregates, which were absent or barely detectable at 1 mM and 2.5 mM NH4Cl (data not 
shown) but evident at 5 mM (see below). Therefore, morphological and biochemical effects 
of hyperammonemia were further analyzed by treating aggregate cultures with 5 mM NH4Cl. 
 
NH4Cl exposure impaired axonal growth in developing mixed-cell aggregates 
Control mixed-cell aggregate cultures at day 13 presented a characteristic distribution of cells, 
including a peripheral zone with a low density of cell bodies (Fig. 1A,B; asterisk) in which 
fibers were prevalent (Fig. 1C). These fibers were NF-M positive, using the monoclonal anti-
NF-M NN-18 antibody which did not stain neuronal soma (Fig. 1D). Aggregates exposed to 5 
mM NH4Cl from days 5 to 13 showed more densely packed cell bodies at their periphery 
(Fig. 1K,L), and the almost complete absence of NF-M positive fibers (Fig. 1M,N). Another 
monoclonal anti-NF-M antibody, RMO-44, localized NF-M in neuronal cell bodies but not in 
fibers (Fig. 1E). The somatic expression of NF-M was not altered by 5 mM NH4Cl exposure 
(Fig. 1O). Western blot analysis of NF-M showed that NH4Cl exposure caused a drastic 
decrease of NF-M (3-fold using NN-18, Fig. 1U; and 2-fold using RMO-44, Fig. 1V). 
 
The specificity of NN-18 and RMO-44 antibodies for NF-M recognition was further 
characterized by dephosphorylation of proteins in situ using alkaline phosphatase. 
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Dephosphorylation abolished most of the NN-18 staining in fibers of the aggregate periphery 
(Fig. 2A,B) and induced RMO-44 NF-M immunoreactivity in distal fibers located at the 
aggregate periphery and in proximal fibers connecting neuronal cell bodies to the aggregate 
periphery (Fig. 2C,D). This indicates that NN-18 predominantly recognized phosphorylated 
NF-M, whereas RMO-44 predominantly recognized non-phosphorylated NF-M. Thus, the 
absence of NN-18 anti-NF-M staining after NH4Cl exposure (Fig. 1N) suggests that 
ammonium exposure inhibited NF-M phosphorylation. Fibers located at the aggregate 
periphery and containing phosphorylated NF-M were most probably axons, as suggested by 
analyzing the expression of GAP43, an axonal growth cone marker. In control day 13 mixed-
cell aggregates, GAP43 was highly expressed in the same peripheral zone exhibiting strong 
NF-M staining by NN-18 (Fig. 3A). Like for NF-M, the GAP43 staining was lost in this 
region after NH4Cl exposure (Fig. 3G). Interestingly, a strongly GAP43 immunoreactive zone 
appeared at the border of the aggregates (Fig. 3G, bracket). Western blotting analysis of 
GAP43 after NH4Cl exposure showed a small decrease of the GAP43 signal (-20%, Fig. 3M). 
 
In day 13 mixed-cell aggregates, glial cells were identified by immunohistochemical staining 
for GFAP (specific for astrocytes, Fig. 3B) and MBP (specific for oligodendrocytes, Fig. 3C). 
NH4Cl exposure increased the number of GFAP positive astrocytic processes, particularly at 
the aggregate border (Fig. 3H, bracket), whereas no significant effect was found for 
oligodendrocytes (Fig. 3I). Western blotting analysis of GFAP after NH4Cl exposure showed 
a 2.2-fold increase of the GFAP signal (Fig. 3N). 
 
 
 
NH4Cl exposure decreased intracellular Cr, PCr and ADP in developing mixed-cell 
aggregates 
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To test whether energy rich phosphates and/or the Cr/PCr/CK system were involved in 
ammonium induced axonal growth impairment, we measured intracellular levels of Cr, PCr, 
ATP, ADP and AMP in mixed-cell aggregates (Table 2). NH4Cl exposure reduced Cr, PCr 
and ADP significantly (83, 75 and 69 % of controls, respectively), whereas no significant 
effect was observed for ATP and AMP content. 
 
Creatine prevented NH4Cl induced axonal growth impairment in developing mixed-cell 
aggregates 
Because Cr and PCr were decreased in NH4Cl exposed aggregates, we examined whether Cr 
had a protective effect on axonal growth under NH4Cl exposure. By immunohistochemistry 
with the NN-18 antibody, we found indeed that 1 mM Cr added to NH4Cl exposed aggregates 
protected the peripheral axons, their expression of NF-M as well as NF-M phosphorylation 
(Fig. 1P-S; see controls: A-D; and NH4Cl exposure: K-N), whereas Cr given alone increased 
the density of NF-M positive peripheral axons (Fig. 1F-I). Immunohistochemistry with RMO-
44 did not reveal any difference in NF-M expression between aggregates treated with Cr and 
controls (Fig. 1J,E) nor between NH4Cl+Cr and NH4Cl exposed aggregates (Fig. 1T,O). 
Analysis of NF-M by western blotting showed that Cr co-treatment maintained NF-M at 
control levels in mixed-cell aggregates exposed to NH4Cl (NN-18, Fig. 1U) or showed partial 
protection (RMO-44, -25% as compared to controls, +50% as compared to NH4Cl exposure, 
Fig. 1V), whereas Cr exposure alone did not affect the NF-M level as compared to controls 
(Fig. 1U,V). A higher concentration of Cr (25 mM) was also tested, which did not improve 
the protection of axonal growth under ammonium exposure, as compared to that obtained 
with 1 mM Cr (data not  shown). 
 
GAP43 expression was partially protected in the peripheral NF-M positive region of NH4Cl 
exposed aggregates co-treated with Cr (Fig. 3J, asterisk; see control: A; and NH4Cl exposure: 
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G). However, the border of the aggregates was strongly positive for GAP43, as after exposure 
to NH4Cl alone (Fig. 3J,G, bracket). As compared to controls, Cr given alone increased the 
GAP43 signal in the center of the aggregates (Fig. 3D,A). By western blot analysis, no 
difference was observed for GAP43 expression between Cr exposed cultures and controls, nor 
between NH4Cl+Cr and NH4Cl exposed cultures (Fig. 3M). Astrocytes and oligodendrocytes 
presented similar patterns of expression for GFAP and MBP in cultures treated with Cr and in 
controls (GFAP Fig. 3E,B; MBP Fig. 3F,C) as well as in NH4Cl+Cr and NH4Cl treated 
aggregates (GFAP Fig. 3K,H; MBP Fig. 3L,I). 
 
No restoration of nor increase in intracellular PCr, ATP or ADP could be observed in mixed-
cell aggregates co-treated with 5 mM NH4Cl and 1 mM Cr as compared to cultures exposed to 
NH4Cl only (Table 2), whereas intracellular Cr was increased significantly (170% of 
controls). Cr was efficiently taken up by mixed-cell aggregates exposed to 1 mM Cr only 
(190% of controls, p < 0.001); however their PCr, ATP or ADP content was not modified. 
NH4Cl induced a significant decrease of intracellular Cr in aggregates exposed to 1mM Cr 
(75% of Cr alone exposure, p < 0.005). 
 
Creatine did not prevent the NH4Cl induced axonal growth impairment in developing 
neuron-enriched aggregates 
Untreated neuron-enriched aggregate cultures also developed a peripheral zone with a low 
density of cell bodies, but devoid of the glial cell lining found at the border of mixed-cell 
aggregates (Fig. 4A vs. 1B; compare also staining for GFAP, Fig. 4D vs. 3B; and MBP, Fig. 
4E vs. 3C). Like in mixed-cell cultures, the number of axons that developed in the aggregate 
periphery of day 13 neuron-enriched aggregates (Fig. 4B) was decreased under NH4Cl 
exposure, as was NF-M phosphorylation (Fig. 4K,L). In contrast to mixed-cell cultures 
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however, Cr co-treatment of neuron-enriched cultures did not prevent the NH4Cl induced 
axonal growth impairment nor the decrease of NF-M phosphorylation (Fig. 4P,Q; see controls 
Fig. 4A,B; and NH4Cl exposure, Fig. 4K,L). In contrast to mixed-cell cultures, Cr given alone 
did not change the density of NF-M positive axons (Fig. 4F,G; see controls Fig. 4A,B). 
Similar densities of NF-M positive neuronal cell bodies stained with RMO-44 were found in 
controls, NH4Cl, and NH4Cl+Cr exposed neuron-enriched aggregates (Fig. 4C,M,R). 
However, exposure to Cr alone caused an increased density of neuronal cell bodies, as well as 
a less intense staining of the non-phosphorylated NF-M around the cell nucleus (Fig. 4H). 
Analysis by western blotting and staining with either NN-18 or RMO-44 showed that NF-M 
was quantitatively decreased in NH4Cl exposed neuron-enriched aggregates, and that Cr co-
treatment of NH4Cl exposed cultures did not protect NF-M expression (Fig. 4U,V). 
 
The presence of few remaining astrocytes in neuron-enriched cultures was confirmed by anti-
GFAP labeling (Fig. 4D; see mixed-cell cultures Fig. 3B). NH4Cl exposure (with or without 
Cr co-treatment) did not change the density of GFAP positive astrocytic processes, but caused 
an increase in the size of astrocyte cell bodies, reminiscent of Alzheimer type II astrocytes 
(Fig. 4N,S, arrows; see controls Fig. 4D). Exposure to Cr alone did not modify the GFAP 
level, nor the astrocyte soma diameter, nor the astrocytic process density (Fig. 4I; see controls 
Fig. 4D). The complete absence of oligodendrocytes in neuron-enriched aggregates was 
confirmed by anti-MBP staining in both controls and treated cultures (Fig. 4E,J,O,T). 
 
 
Creatine and phosphocreatine levels in neuron-enriched cultures were not altered by 
NH4Cl exposure 
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In control conditions, the Cr concentration found in neuron-enriched aggregates was 10-fold 
lower than in mixed-cell cultures (compare Tables 3 to 2), suggesting that neurons had a 
limited capacity to synthesize Cr. In contrast to mixed-cell aggregates, NH4Cl exposure of 
neuron-enriched cultures did not affect intracellular Cr and PCr (Table 3), but ATP, ADP and 
AMP were significantly lower (67%, 58% and 50% of controls, respectively). Cr co-treatment 
did not attenuate the NH4Cl induced decrease of adenine nucleotides, nor did it modify the 
PCr concentration (Table 3). Neuron-enriched cultures were able to take up Cr efficiently, as 
exposure to 1mM Cr increased intracellular Cr 8.4-fold when compared to control levels 
(Table 3, p < 0.001; compare to 1.9-fold only in mixed-cell cultures, Table 2), and 3.5-fold 
when comparing NH4Cl+Cr with NH4Cl exposed cultures (p < 0.01). NH4Cl caused a 
significant decrease of Cr in neuron-enriched aggregates exposed to 1mM Cr (40% of Cr 
alone exposure, p < 0.005). 
 
Neurons affected by NH4Cl exposure in day 13 mixed-cell aggregates are cholinergic 
The neuronal identity of axons affected by NH4Cl was analyzed by immunohistochemistry 
against ChAT, GAD 65/67 kD and EAAT3 to discriminate between cholinergic, GABA-ergic 
and glutamatergic neurons respectively. ChAT was expressed in neuronal cell bodies of day 
13 aggregates, as well as in punctuate formations localized in the peripheral zone where axons 
grow (Fig. 5A). Following NH4Cl exposure, ChAT immunostaining decreased in the 
peripheral axonal region (Figure 5B), but was maintained in aggregates exposed to NH4Cl+Cr 
(Fig. 5D). Cr alone did not modify the punctuate staining of ChAT in the aggregate periphery, 
but increased it in neuronal cell bodies (Fig. 5C). GAD 65/67 kD was localized in numerous 
neuronal cell bodies, and its expression was not modified by NH4Cl (Fig. 5E,F). At day 13, no 
expression of the glutamate transporter EAAT3 could be detected in the aggregates (data not 
shown). 
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 NH4Cl and creatine exposure did not alter axons of mature mixed-cell aggregates 
To investigate whether NH4Cl affected axons also in mature neurons, aggregates were 
exposed to 5 mM NH4Cl and/or 1 mM Cr from days 20 to 28, i.e. at a stage where neurons 
progressively undergo synaptogenesis and myelination (Honegger and Monnet-Tschudi, 
2001). At day 28, the peripheral dense fiber zone was clearly visible (Fig. 6A,B) and richer in 
number of axons expressing NF-M than at day 13 (Fig. 6C, compare to Fig. 1D). NH4Cl (5 
mM) exposure did not affect axons of mature aggregates (Fig. 6D). Aggregates treated with 1 
mM Cr (Fig. 6E) or with NH4Cl+Cr (Fig. 6F) were also comparable to control aggregates 
(Fig. 6C). Quantitative analysis of NF-M by western blotting, using NN-18, did not reveal 
any significant difference between controls and treated cultures (Fig. 6G). 
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Discussion 
 
Ammonium exposure impairs cholinergic axonal growth, decreases NF-M and inhibits 
NF-M phosphorylation 
We provide the first experimental demonstration of neuronal fiber growth impairment under 
ammonium exposure, together with a decrease in NF-M protein and an inhibition of NF-M 
phosphorylation. This is in line with the growing number of recently described neurological 
pathologies showing abnormal expression or phosphorylation of neuronal cytoskeleton 
proteins such as neurofilaments (NFs) or microtubule associated proteins (Hirokawa and 
Takeda, 1998; Julien, 1999; Saez et al., 1999; Sanchez et al., 2000). Our results are consistent 
with clinical findings in hyperammonemic neonates or infants presenting brain lesions 
compatible with neuronal fiber loss or defects of neurite outgrowth, such as cortical atrophy, 
ventricular enlargement, demyelination or gray and white matter hypodensities (Msall et al., 
1984; Harding et al., 1984; Wakamoto et al., 1999), which can be acquired in utero (Filloux et 
al., 1986). 
 
Understanding ammonium toxicity to neurons implied to identify impaired NF-M positive 
fibers. NN-18 and RMO-44 anti-NF-M antibodies are directed against phosphorylation 
independent epitopes and both equally recognize NF-M in denaturing SDS-PAGE conditions 
(Lee et al., 1987; Harris et al., 1991; and this work). On cryosections however, we showed 
that NN-18 stained fibers but not neuronal cell bodies, whereas RMO-44 stained neuronal 
soma, but not fibers. We showed moreover that protein dephosphorylation on cryosections 
suppressed the staining of fibers by NN-18 but induced it by RMO-44. Thus, both antibodies 
recognize non-phosphorylated epitopes that are exposed or not depending on changes of NF-
M conformation due to its level of phosphorylation. On histological sections, the epitope 
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recognized by NN-18 appears to be exposed only when NF-M is phosphorylated, whereas 
that recognized by RMO-44 seems exposed only when NF-M is non-phosphorylated. 
Accordingly, fibers at aggregate periphery preferentially contain phosphorylated NF-M, 
whereas neuronal soma essentially contain non-phosphorylated NF-M. Our findings may 
explain why NN-18 does not stain neuronal soma except in case of hyperphosphorylated NF-
M accumulation (Harris et al., 1991; Nguyen et al., 2001), and why RMO-44 preferentially 
labels neuronal soma (Lee et al., 1987). 
 
NFs are distributed in neuronal soma, dendrites and axons. Non-phosphorylated NFs are 
predominantly found in the somato-dendritic compartment, whereas phosphorylated NFs are 
enriched in axons (Rosenstein and Krum, 1996; Brown, 1998; Ulfig et al., 1998). Moreover, 
GAP43 and ChAT showed a localization similar to that of NN-18 stained NF-M, and reacted 
like it under NH4Cl and/or Cr exposure. GAP43 is found in growth cones of axons 
exclusively (Goslin et al., 1988), and ChAT is recognized as presynaptic axonal marker 
(Phelps et al., 1985). Taken together, these data suggest that NN-18 stained axons 
specifically. 
 
Cholinergic, GABA-ergic and glutamatergic neurons differentiate in the brain aggregate 
culture system (Pardo and Honegger, 1999; Honegger and Monnet-Tschudi, 2001). Data 
presented here suggest that early in development, axons impaired by NH4Cl belong to 
cholinergic neurons. This does not exclude that ammonium could also impair axonal growth 
of glutamatergic and GABA-ergic neurons later-on in development, as glutamatergic 
neurotransmission and GAD activity are altered by hyperammonemia (Albrecht, 1998; 
Braissant et al., 1999b). Our findings are in line with data obtained in the spf mouse, a model 
of hyperammonemia caused by ornithine transcarbamylase deficiency, which shows 
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cholinergic neuronal loss in cerebral cortex (Ratnakumari et al., 1994). Lack of elongation of 
cholinergic axons during cortical development may provide a basis for understanding some of 
the severe cognitive defects caused by hyperammonemia. 
 
NH4Cl induced inhibition of axonal growth depends on intracellular Cr 
NH4Cl exposure of day 13 mixed-cell aggregates impaired axonal growth and decreased 
intracellular levels of Cr, PCr and ADP. Cr co-treatment under NH4Cl exposure protected 
axonal growth, but neither restored nor increased PCr, ATP and ADP levels. This suggests 
that under NH4Cl exposure, the rescue of axonal growth by Cr does not depend on high 
energy phosphates, which remain lowered under NH4Cl+Cr exposure and are known to 
decrease in the hyperammonemic CNS (Ratnakumari et al., 1992). We cannot exclude 
however that concentration changes in specific cell types or in subcellular compartments (e.g. 
mitochondria) remain undetected. Intracellular Cr was decreased by 60% in neuron-enriched 
but only by 25% in mixed-cell aggregates exposed to NH4Cl+Cr as compared to Cr exposure, 
suggesting that NH4Cl exposure reduced the capacity to accumulate Cr in neurons 
preferentially. 
 
Glial dependency of axonal protection by creatine under NH4Cl exposure 
Cr added to the culture medium was sufficient to protect axonal growth in NH4Cl exposed 
mixed-cell aggregates, but not in neuron-enriched cultures, suggesting that the mechanism of 
axon protection by Cr depends on glial cells, be it astrocytes or oligodendrocytes. In case of 
an astrocyte dependent mechanism, the very few astrocytes still present in neuron-enriched 
cultures might suffice for supporting axonal growth in control conditions, but not for 
protecting axons exposed to NH4Cl. The absence of oligodendrocytes in neuron-enriched 
cultures might also suggest an oligodendrocyte dependent mechanism. Since Cr is taken up 
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by neuron-enriched cultures without protecting axons exposed to NH4Cl, it is unlikely that Cr 
per se is the sole glia-derived axonal growth promoting factor. Our findings preferentially 
support the hypothesis that a glial factor is needed, which is modified through Cr in glial cells 
(e.g. by the Cr/PCr/CK system), released and used by neurons to promote axonal growth. This 
would still allow axonal growth in control neuron-enriched cultures, as they are grown in a 
culture medium conditioned by mixed-cell cultures (Honegger and Monnet-Tschudi, 2001). 
As we have shown that axons do not grow in neuron-enriched aggregates exposed to 
ammonium, it also implies that NH4Cl has a direct neuronal inhibitory effect on axonal 
growth that cannot be prevented in absence of glial cells, but is counteracted by Cr co-
treatment in mixed-cell aggregates. 
 
The glial mechanism of axonal growth protection might involve protein phosphorylation, 
which is directly linked to cell content in high energy phosphates and Cr/PCr/CK system, 
altered in glial cells under ammonium exposure (Neary et al., 1987; Schliess et al., 2002) and 
was proposed as a main signaling pathway in axon/glia inter-relationships (Witt and Brady, 
2000). Cr dependent modification of glial protein phosphorylation could support axonal 
growth, which per se is regulated through phosphorylation of axonal cytoskeleton proteins 
(e.g. NFs) under direct influence of oligodendrocytes (de Waegh et al., 1992). Such a 
mechanism is supported by our data, namely the NH4Cl induced inhibition of NF-M 
phosphorylation that is counteracted by a Cr co-treatment. 
 
NH4Cl exposure does not alter axonal morphology in mature aggregates 
We have shown that ammonium impaired axons in developing aggregates, but did not affect 
them in mature cultures. The absence of NH4Cl effect on mature axons could be due to fully 
differentiated astrocytes, which have a higher capacity for ammonium detoxification 
  20 
(Butterworth, 1993). Alternatively, protective factors released by target postsynaptic neurons 
to their presynaptic counterparts could be involved (Keith and Wilson, 2001). This difference 
in vulnerability of the brain is also found clinically, as hyperammonemia causes irreversible 
CNS symptoms compatible with axonal loss in neonates and infants but not in adults 
(Brusilow and Horwich, 2001). Evidence for direct coupling of Cr/PCr/CK system to growth 
cone activity and axonal growth (Wang et al., 1998) and Cr/PCr age dependency of CNS in 
the first weeks of postnatal life (Tsuji et al., 1995) also support the difference we found 
between developing and mature aggregates. It suggests a higher CNS sensitivity to Cr 
variations in young children than in adulthood. 
 
The brain cell aggregate culture system as a model to study CNS hyperammonemia 
Axonal growth was altered in developing brain cell aggregates by 5 mM NH4Cl exposure. 
This concentration mimicked the in vivo extracellular ammonium level found in the brain of 
experimental hyperammonemic rats, which was measured as high as 5mM (Swain et al., 
1992). For human hyperammonemic patients, data are lacking on extracellular brain 
ammonium concentration. However, serum levels of ammonium leading to irreversible 
damage to the developing CNS can peak as high as 2mM, usually following a chronic 
hyperammonemia in the range of 200µM (Butterworth, 1998; Bachmann, 2002a). Brain cell 
aggregate cultures fulfilled the requirements that irreversible ammonium toxicity to CNS 
should be studied in models mimicking brain complexity (Butterworth, 1998; Braissant et al., 
1999a and b) but devoid of confusing variables due to secondary effects of hyperammonemia 
found in animal studies (Bachmann, 1992). Our findings are in agreement with data showing 
that hyperammonemia stimulates brain glycolysis with release of lactate into CSF and causes 
ammonium detoxification through astrocytic glutamine synthesis, which can lead to gliosis 
and occurrence of Alzheimer type II astrocytes (Butterworth, 1998). Moreover, GAP43, an 
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exclusive marker of axonal growth cone in physiological conditions, was induced in the 
GFAP positive border of NH4Cl exposed aggregates, as in reactive astrocytes (Sensenbrenner 
et al., 1997).  
 
Conclusions 
We have shown that glial Cr can protect axonal growth under ammonium exposure. This 
work exemplifies the importance of neuron-glial interactions in the pathophysiology of 
hyperammonemia. Future work will aim at identifying those factors modified through glial Cr 
that support axonal growth and are impaired by hyperammonemia, and at understanding 
changes in brain Cr metabolism and transport under ammonium exposure. This study also 
suggests that one should assess means for sustaining the CNS Cr level of hyperammonemic 
neonates and infants, to prevent irreversible brain damage due to impairment of axonogenesis. 
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Figure legends 
 
Figure 1: Axons are missing and NF-M is decreased in NH4Cl exposed day 13 mixed-cell 
aggregates. Creatine, added to NH4Cl exposure, rescues axons and NF-M. 
Cultures grown from days 5 to 13 with or without 5mM NH4Cl and/or 1mM Cr. 
Cryosections stained by hematoxylin (Hem.; A,B,F,G,K,L,P,Q), Bielschowsky’s silver 
impregnation (Silver; C,H,M,R) and immunohistochemistry against NF-M (D,I,N,S: NN-18 
antibody; E,J,O,T: RMO-44 antibody). A-E: Controls; F-J: Cr; K-O: NH4Cl; P-T: 
NH4Cl+Cr. Panels B-E, G-J, L-O and Q-T are higher magnifications of the area depicted in 
A. The dense peripheral axonal zone is indicated by an asterisk. Bar: 100 µm. 
U,V: NF-M analysis by western blotting, with NN-18 (U; 20 µg proteins per lane) and 
RMO44 (V; 10 µg protein per lane) antibodies. Means ± SD of 3 separate cultures.   
 
Figure 2: NN-18 and RMO-44 anti-NF-M antibodies recognize phosphorylated, 
respectively non-phosphorylated, NF-M in native conformation. Mixed-cell aggregates at 
13 days of culture. A,C: Controls; B,D: Dephosphorylation by alkaline phosphatase. 
Cryosections were stained by immunohistochemistry against NF-M (A,B: NN-18 antibody; 
C,D: RMO-44 antibody). Arrow: neuronal cell body; arrowhead: proximal axon, arising from 
neuronal cell body and growing towards aggregate periphery ; asterisk: peripheral zone 
enriched in axons. Bar: 100 µm. 
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Figure 3: GAP43, an axonal growth cone marker, is decreased by NH4Cl exposure, and 
rescued by Cr co-treatment, in the peripheral axonal zone of the aggregates. Ammonium 
exposure induces GAP43 and increases GFAP in reactive astrocytes of the aggregate 
border. 
Cultures treated from days 5 to 13 with or without 5mM NH4Cl and/or 1mM Cr. 
Cryosections stained by immunohistochemistry against GAP43 (A,D,G,J), GFAP (B,E,H,K) 
and MBP (C,F,I,L). A,D,G,J were counterstained by hematoxylin. A-C: Controls; D-F: Cr; 
G-I: NH4Cl; J-L: NH4Cl+Cr. The dense peripheral axonal zone is indicated by an asterisk. 
Highly GFAP-positive astrocytes in the border of aggregates are shown by brackets. Bar: 100 
µm. 
M,N: GAP43 (M) and GFAP (N) analysis by western blotting (10 µg proteins per lane). 
Means ± SD of 3 separate cultures. 
 
Figure 4: Cr, added to NH4Cl exposed day 13 neuron-enriched aggregates, do not rescue 
developing axons and NF-M levels. 
Cultures treated from days 5 to 13 with or without 5mM NH4Cl and/or 1mM Cr. 
Cryosections stained by hematoxylin (A,F,K,P) and immunohistochemistry against NF-M 
(B,G,L,Q: NN-18 antibody; C,H,M,R: RMO-44 antibody), GFAP (D,I,N,S) and MBP 
(E,J,O,T). A-E: Controls; F-J: Cr; K-O: NH4Cl; P-T: NH4Cl+Cr. The dense peripheral 
axonal zone is indicated by an asterisk. Arrows point to GFAP-positive giant astrocytes in 
NH4Cl exposed cultures. Bar: 100 µm. 
U,V: NF-M analysis by western blotting, with NN-18 (U; 20 µg proteins per lane) and 
RMO44 (V; 10 µg protein per lane) antibodies. Means ± SD of 3 separate cultures. 
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 Figure 5: Cholinergic axons of day 13 mixed-cell aggregates are affected by NH4Cl 
exposure and rescued by Cr co-treatment. 
Aggregates were treated from day 5 to day 13 with or without 5mM NH4Cl and/or 1mM 
creatine. 
Immunohistochemistry against ChAT (A-D) and GAD 65/67 kD (E,F). A,E: controls; B,F: 
NH4Cl; C: Cr; D: NH4Cl+Cr. The dense peripheral axonal zone is indicated by an asterisk. 
Bar: 100 µm.  
 
Figure 6: NH4Cl and Cr do not affect axons and NF-M in day 28 mature mixed-cell 
aggregates. 
Cultures were treated from days 20 to 28 with or without 5mM NH4Cl and/or 1mM Cr. 
A,B: Hematoxylin staining of day 28 control aggregates at low (A) and high (B) 
magnification. C-F: Immunohistochemistry against NF-M (NN-18 antibody). C: control; D: 
NH4Cl; E: Cr; F: NH4Cl+Cr. Panels B-F are higher magnifications of the area depicted in A. 
The dense peripheral axonal zone is indicated by an asterisk. Bar: 100 µm. 
G: NF-M analysis by western blotting (NN-18 antibody; 15 µg proteins per lane). Means ± 
SD of 3 separate cultures. 
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Table 1 : NH4Cl dose dependent uptake and release of ammonium, glucose and lactate 
by mixed-cell aggregate cultures a. 
 
  Days 5 => 8 Days 8 => 11 Days 11 => 13 
        
NH4Cl [mM]  Ammonium 
0  -26 ±   1  -4 ± 1  -2 ±   1  
1.0  -55 ± 13 <0.001 -31 ± 4 <0.001 -38 ±   1 <0.001 
2.5  -113 ± 19 <0.001 -96 ± 2 <0.001 -114 ±   1 <0.001 
5.0  -176 ± 16  <0.001 -250 ± 2 <0.001 -264 ± 10 <0.001 
        
  Glucose 
0  -399 ± 19  -464 ± 12  -756 ±   4  
1.0  -372 ± 32 NS -389 ± 22 <0.01 -656 ± 48 <0.05 
2.5  -525 ± 32 <0.01 -468 ±   7 NS -835 ± 17 <0.01 
5.0  -672 ± 21 <0.001 -623 ± 19 <0.001 -1026 ±   7 <0.001 
        
  Lactate 
0  137 ±   5  166 ±   6  685 ± 26  
1.0  152 ± 18 NS 149 ± 39 NS 549 ± 21 <0.01 
2.5  269 ± 22 <0.001 153 ± 22 NS 696 ± 73 NS 
5.0  431 ± 34 <0.001 370 ± 41 <0.001 1137 ± 22 <0.001 
 
a Net uptake (net decrease in culture medium) and release (net increase in culture medium) by 
aggregates, calculated from days 5 to 8, 8 to 11 and 11 to 13, and expressed as nmol · h-1 · (mg 
prot)-1. Measures were taken at days 5 (start of treatment), 8 (before and after medium 
change), 11 (before and after medium change) and 13 (end of treatment). Proteins were 
measured at day 13. Data are means ± SD of 3 separate cultures. Statistical p are shown 
(Student’s t-test) for comparison to controls (NH4Cl = 0 mM); NS: not significant. 
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 Table 2. Intracellular creatine, phosphocreatine, ATP, ADP and AMP in mixed-cell aggregates at day 13 of culture a. 
 
Treatments Control Cr NH4Cl NH4Cl+Cr  
NH4Cl [mM] 0 0 5 5 Comparisons 
Creatine [mM] 0 1 0 1 NH4Cl vs. Controls NH4Cl+Cr vs. NH4Cl 
Creatine   178.6 ± 5.8 340.2 ± 3.5 147.7 ± 4.1 255.5 ± 25.6 < 0.01 < 0.01 
Phosphocreatine 13.0 ± 0.4 12.1 ± 0.3 9.7 ± 0.8 9.8 ±   0.5 < 0.05 NS 
ATP 5.5 ± 0.7 7.0 ± 0.9 4.5 ± 2.1 3.1 ±   0.2 NS NS 
ADP 39.3 ± 2.3 37.6 ± 2.9 27.2 ± 1.5 29.1 ±   3.8 < 0.01 NS 
AMP 17.2 ± 0.4 18.8 ± 1.4 19.6 ± 7.3 15.3 ±   4.2 NS NS 
 
a Data are expressed as nmol · (mg prot)-1 and are means ± SD of 3 separate cultures. Statistical p are shown (Student’s t-test; NS: not 
significant). 
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 Table 3: Intracellular creatine, phosphocreatine, ATP, ADP and AMP in neuron-enriched aggregates at day 13 of culture a.  
 
Treatments Control Cr NH4Cl NH4Cl+Cr  
NH4Cl [mM] 0 0 5 5 Comparisons 
Creatine [mM] 0 1 0 1 NH4Cl vs. Controls NH4Cl+Cr vs. NH4Cl 
Creatine 17.4 ± 2.0 138.6 ± 17.9 16.3 ± 1.6 56.2 ±  9.3 NS < 0.01 
Phosphocreatine 4.4 ± 1.9 6.8 ±   2.1 4.1 ± 0.7 4.8 ±   1.6 NS NS 
ATP 6.7 ± 0.9 9.1 ±   0.6 4.5 ± 0.6 4.3 ±   0.8 < 0.05 NS 
ADP 3.3 ± 0.4 3.7 ±   0.3 1.9 ± 0.2 2.0 ±   0.4 < 0.05 NS 
AMP 7.6 ± 1.1 9.4 ±   2.0 3.8 ± 0.4 3.7 ±   0.1 < 0.01 NS 
 
a Data are expressed as nmol · (mg prot)-1 and are means ± SD of 3 separate cultures. Statistical p are shown (Student’s t-test; NS: not 
significant). 
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